Clinical Trial Update: Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating AUY922 in combination with trastuzumab in patients with advanced HER2-positive breast cancer previously treated with trastuzumab ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AUY922 (luminespib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced HER2-positive Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED